Growth hormone is not released continuously — it is secreted in pulses, with the largest pulse occurring shortly after sleep onset, coinciding with the first period of slow-wave sleep. This nocturnal GH pulse accounts for the majority of daily GH secretion and is responsible for much of the tissue repair and cellular regeneration that sleep provides.
CJC-1295: Extended GHRH Signaling
CJC-1295 is a modified analog of GHRH with an extended half-life. Where native GHRH has a half-life of minutes, CJC-1295 (with DAC) has a half-life of 6–8 days, allowing once-weekly dosing. In clinical studies, CJC-1295 increased GH secretion by 2–10 fold and IGF-1 levels by 1.5–3 fold with effects persisting for weeks.
Ipamorelin: The Clean GH Secretagogue
Ipamorelin is a GHSR agonist — it triggers GH release through the ghrelin receptor pathway, distinct from the GHRH pathway that CJC-1295 uses. This mechanistic difference is the basis for synergy: by stimulating GH release through two independent pathways simultaneously, the stack produces substantially larger GH pulses than either agent alone.
Ipamorelin is the cleanest GHSR agonist because it releases GH with minimal effect on other pituitary hormones. Unlike GHRP-2 or GHRP-6, Ipamorelin does not significantly elevate cortisol or prolactin — a meaningful advantage for sleep and recovery protocols.
Clinical Effects
Patients consistently report improved sleep quality — specifically increased slow-wave sleep time, faster onset, and more restorative sleep. Recovery effects include accelerated soft tissue healing, reduced post-exercise soreness, improved body composition, and enhanced energy. Standard protocol is subcutaneous injection 30–60 minutes before sleep, in a fasted state.